NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $9.99 +0.04 (+0.40%) Closing price 04:00 PM EasternExtended Trading$9.98 -0.01 (-0.05%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immatics Stock (NASDAQ:IMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immatics alerts:Sign Up Key Stats Today's Range$9.92▼$10.3850-Day Range$8.87▼$11.6252-Week Range$5.05▼$12.41Volume837,218 shsAverage Volume345,188 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$20.80Consensus RatingModerate Buy Company Overview Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision. At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells. Building on these discoveries, the company’s ACTengine® program engineers autologous T cells with optimized TCRs targeting selected antigens, while the ACTallo® portfolio focuses on off-the-shelf, allogeneic T cell therapies designed for broader patient access. In parallel, Immatics pursues TCR-based bispecific molecules and cancer vaccine candidates to expand its immunotherapy toolbox. Immatics’ pipeline includes multiple clinical-stage cell therapy candidates, such as IMA201, IMA202 and IMA203, which are being evaluated in a range of solid tumor indications. The company has entered strategic collaborations with leading biopharmaceutical companies to advance certain programs, and it continues to explore partnerships that can accelerate the development and commercialization of its TCR-based assets. These alliances support both late-stage clinical development and global regulatory planning. Founded in 2000 as a spin-out from the German Cancer Research Center, Immatics maintains its global headquarters in Tübingen, Germany, with a significant R&D presence in Houston, Texas. The company is led by Chief Executive Officer Harpreet Singh and a management team with extensive experience in immuno-oncology, cell therapy and pharmaceutical development. Immatics’ dual-site structure enables close collaboration with academic institutions and biopharma partners across Europe and North America.AI Generated. May Contain Errors. Read More Immatics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreIMTX MarketRank™: Immatics scored higher than 39% of companies evaluated by MarketBeat, and ranked 596th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingImmatics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmatics has a consensus price target of $20.80, representing about 108.2% upside from its current price of $9.99.Amount of Analyst CoverageImmatics has only been the subject of 3 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.67) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.35% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 9.03.Change versus previous monthShort interest in Immatics has recently increased by 17.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Immatics this week, compared to 2 articles on an average week.Search Interest5 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by Insiders3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMTX Stock News HeadlinesImmatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 2, 2026 | americanbankingnews.comImmatics: PRAME Is Becoming More Than A Single-Asset StoryJune 16, 2026 | seekingalpha.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 6 at 1:00 AM | Porter & Company (Ad)Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingJune 1, 2026 | globenewswire.comImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 ...May 31, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Amgen (AMGN)May 31, 2026 | theglobeandmail.comImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung CancerMay 31, 2026 | globenewswire.comImmatics N.V. Reports Promising Phase 1 Results for IMA203CD8 PRAME Cell Therapy in Gynecologic and Synovial Sarcoma CancersMay 30, 2026 | quiverquant.comQSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.50 at the beginning of the year. Since then, IMTX shares have decreased by 4.9% and is now trading at $9.99. How were Immatics' earnings last quarter? Immatics N.V. (NASDAQ:IMTX) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.08. The business earned $8.81 million during the quarter, compared to analyst estimates of $9.79 million. Immatics had a negative net margin of 572.35% and a negative trailing twelve-month return on equity of 47.36%. How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and Qualcomm (QCOM). Company Calendar Last Earnings5/12/2026Today7/06/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IMTX's financial health is in the Green zone, according to TradeSmith. IMTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMTX CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Price Target for Immatics$20.80 High Price Target$25.00 Low Price Target$17.00 Potential Upside/Downside+108.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$222.26 million Net Margins-572.35% Pretax Margin-574.58% Return on Equity-47.36% Return on Assets-39.35% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual Sales$54.60 million Price / Sales24.53 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book2.44Miscellaneous Outstanding Shares134,070,000Free FloatN/AMarket Cap$1.34 billion OptionableOptionable Beta1.32 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IMTX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
